A Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

• Status: No longer available
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to collect additional safety data during treatment with abiraterone acetate plus prednisone or prednisolone among adult participants with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) who reside in areas in which abiraterone acetate is not yet available for this indication through local healthcare providers, and who are not eligible for enrollment into an available ongoing clinical study of abiraterone acetate.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Janssen Research & Development, LLC
• Treatments: Abiraterone Acetate; Methylprednisolone; Methylprednisolone acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate; Prednisone

Criteria

Inclusion Criteria:

• Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell histology

• Not have received cytotoxic chemotherapy regimens for metastatic castration-resistant prostate cancer

• Have prostate cancer progression as assessed by the investigator with prostate-specific antigen progression according to Prostate Cancer Working Group 2 criteria

• Have asymptomatic or mildly symptomatic prostate cancer

• Have ongoing androgen deprivation with serum testosterone <50 ng/dL (<2.0 nM)

• Have Eastern Cooperative Oncology Group performance status of <=2

• Laboratory values within protocol-defined parameters

• Adequate liver function according to protocol-defined parameters

• Be able to swallow the study drug whole as a tablet

• Agrees to protocol-defined use of effective contraception

Exclusion Criteria:

• Eligible for another study of abiraterone acetate that is open to enrollment

• Has received abiraterone acetate in the past or was enrolled in Studies COU-AA-301 or COU-AA-302

• Has serious or uncontrolled co-existent non-malignant disease, including active and uncontrolled infection

• Has uncontrolled hypertension (systolic blood pressure >=160 mmHg or diastolic blood pressure >=95 mmHg); individuals with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive therapy

• Has active or symptomatic viral hepatitis or chronic liver disease

• Has a history of pituitary or adrenal dysfunction

• Has clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or New York Heart Association Class III or IV heart disease or left ventricular ejection fraction of <50% at baseline

• Has atrial fibrillation or other cardiac arrhythmia

• Has known brain metastasis

• Has had prior cytotoxic chemotherapy or biologic therapy for the treatment of castration-resistant prostate cancer (CRPC)

• Has had prior cytotoxic chemotherapy or biologic therapy for the treatment of CRPC

• Has an active infection or other medical condition that would make prednisone/prednisolone use contraindicated

• Has had other anticancer therapy including cytotoxic, radionucleotide, and immunotherapy

• Has had prior systemic treatment with an azole drug; diethylstilbestrol; PC-SPES; spironolactone; and other preparations such as saw palmetto thought to have endocrine effects on prostate cancer, within 4 weeks of Cycle 1 Day 1

• Is currently enrolled in an investigational drug or device study or has participated in such a study within 30 days of Day 1

• Has a condition or situation which, in the investigator's opinion, may put the participant at significant risk, may confound the study results, or may interfere significantly with participant's participation in the study

• Has partners of childbearing potential who are not willing to use a method of birth control with adequate barrier protection as determined to be acceptable by the principal investigator and sponsor during the study and for 13 weeks after last study drug administration